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There is a complex interplay between the structural and other physicochemical properties of new
compounds and the molecules in living organisms. To understand the mechanism of the interactions at
the molecular level, the correlations between the selected properties and their biological responses have
to be examined. With this aim, in this paper, density functional theory (DFT) and LMP2 calculations were
carried out for the 2-acetylpyridine-aminoguanidine ligand, L, and its copper(II) complexes containing
diﬀerent monoanionic ligands. In addition, several parameters, most frequently used for the prediction
of drug-likeness of new compounds, were calculated. The influence of the compounds on the
eﬀectiveness of the reference chemotherapeutic drug cisplatin was determined in vitro, by comparison
of their combination indices (CIs). The drug interactions between cisplatin and the earlier synthesized
ligands L1 (bis(3-chloropyridazine-6-hydrazone)-2,6-diacetylpyridine) and L2 (bis(phthalazine-1-hydrazone)-
2,6-diacetylpyridine) and their Co(III), Ni(II), Cu(II) and Zn(II) complexes, respectively, were also measured. The
ligands L, L2, and L3, as well as their complexes, showed diﬀerent interactions in combination with cisplatin
from strong antagonism of L to strong synergism of 4-L1 and 4-L2. The experimental results and the
calculated parameters were analyzed to evaluate their correlation with the measured interactions. The
thermal stability of the L2HCl ligand and its four copper(II) complexes was determined and the thermal
stability data were correlated to selected calculated molecular descriptors.
Introduction
Schiﬀ bases, as well as their complexes, represent a group of
compounds showing a wide range of biological activities, such
as anticancer and antibacterial properties. Earlier studies of the
activity of 2-acetylpyridine-aminoguanidine and its coordina-
tion compounds with Cu(II) against bacteria and yeasts showed
moderate to low activity to some bacterial species and very low
activity toward fungi.1 On the other hand, both the ligand2–5
and copper(II)6,7 are expected to have other, significant biological
functions. A copper(II) complex with a Schiff base-type ligand in
interaction with human serum albumin increased its target ability
to cancer cells.8 Extensive research is taking place exploring the
biological role of copper complexes with Schiff bases,9–16 listing
here only selected papers published in 2017. Special attention is paid
to their bio-molecular interactions17 as well as their correlations with
selected parameters like the acidity constant of the compounds
and their role in selected biological processes.18 As tools for
assessing bioavailability, often DFT19–22 computations or QSAR23
and docking24 studies are carried out.
Malignant diseases represent one of the most important
factors of morbidity and mortality worldwide, accounting for more
than 8 million deaths in 2015, only preceded by the mortalities
caused by cardiovascular diseases.25 Chemotherapy is a hallmark of
the treatment of these malignancies, often combined with surgical
interventions and radiotherapy.26 The emergence of cancers with a
multidrug-resistant phenotype is an important obstacle to eﬀective
treatment, as these malignancies are found to be resistant to a
variety of anticancer drugs of diﬀerent mechanisms of action and
structure.27 The dosage ofmost of the commercial chemotherapeutic
drugs is limited because of their serious side eﬀects. Hence,
combinations of two or more drugs28,29 are often used in cancer
treatment with the aim of decreasing the side eﬀects and increasing
the sensitivity of the cancer cells toward anticancer agents.30
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Our recent research has been focused on the biological
activity and the reversal of multidrug resistance of new Schiﬀ
bases and their coordination compounds with 3d metals. We
tested the bis(3-chloropyridazine-6-hydrazone)-2,6-diacetylpyridine
ligand, L1, and its Co(III), Ni(II), Cu(II) and Zn(II) complexes for
antiproliferative eﬀects and for the reversal of multidrug resistance
(MDR) in selected tumor cell lines. The structures were theoretically
investigated employing density functional theory (DFT) calculations.
The calculated molecular electrostatic potential (MEP) and the
average local ionization energy (ALIE) surfaces were used to correlate
the eﬀect of the compounds with the inhibition of multidrug
resistance in cancer. The compounds showed a diﬀerent, but
increased inhibitory eﬀect on ABC transporter ABCB1 or P-glyco-
protein.31 Coordination compounds of the same metal centers
with a similar ligand, bis(phthalazine-1-hydrazone)-2,6-diacetyl-
pyridine, L2, exhibited strong to moderate antimicrobial activity
against selected bacteria but had no eﬀect on fungi, while the
ligand itself was practically inactive.32
In this paper, DFT and LMP2 calculations were carried out
for the 2-acetylpyridine-aminoguanidine ligand, L, and its copper(II)
complexes containing diﬀerent monoanionic ligands. In addition,
several parameters, most frequently used for the prediction of drug-
likeness of new compounds, were calculated. The influence of the
compounds on the eﬀectiveness of the reference chemotherapeutic
drug cisplatin was determined in vitro, by comparison of their
combination indices (CIs). The drug interactions between cisplatin
and the earlier synthesized ligands L131 and L2,32 and their Co(III),
Ni(II), Cu(II) and Zn(II) complexes, respectively, were also measured.
The experimental results and the calculated parameters were
analyzed to evaluate their correlation with the measured inter-
actions. The thermal stability of the L2HCl ligand and its four
copper(II) complexes was determined and the thermal stability
data were correlated to selected calculated molecular descriptors.
Results and discussion
DFT results
MEP and ALIE surfaces. Reactive molecule areas can be
identified thanks to the several very useful quantum molecular
descriptors. The MEP surface of the prospective molecule is a
particularly useful quantum-molecular descriptor thanks to
which important molecule sites can be detected by analysis of
charge distribution. In this regard, MEP surfaces are important
tools for the identification of molecule sites sensitive towards
electrophilic and nucleophilic attacks.33–35 MEP values are
calculated according to the following equation:
V ~rð Þ ¼
X ZA
RA ~rj j 
ð
r ~r 0ð Þ
~r 0 ~rj jd~r (1)
In eqn (1), the summation goes over all nuclei A with charge ZA
and coordinate RA, r(r0) is the electron density of the molecule.
The effects of the nuclei or the electrons are reflected by
the sign of the V(r).36,37 Representative MEP surfaces of all
structures investigated in this work are presented in Fig. 1. The
range of the rainbow bar has been chosen according to the
lowest and the highest MEP values in the case of the molecules
investigated in this work.
The results provided in Fig. 1 indicate that the lowest MEP
value has been calculated in the case of the 4-L complex.
Namely, in the vicinity of the nitrogen atom of the thiocyanate
group of the 4-L complex, the lowest MEP value has a value of
almost 57 kcal mol1. A significantly low value of MEP in the
case of the 4-L complex can be predicted for the sulfur atom S2,
characterized by the yellow to reddish color in Fig. 1, corres-
ponding to the MEP value of ca. 50 kcal mol1, which is still
lower than in the case of the lowest MEP values of other complexes.
These results designate complex 4-L as the most sensitive towards
electrophilic attacks, especially the nitrogen and sulfur atoms of its
thiocyanate group. The highest MEP values have been calculated for
the same complex. Namely, the hydrogen atoms of its NH2 and
methyl groups are characterized by the purple color in Fig. 1,
corresponding to MEP values of almost 65 kcal mol1. Therefore,
thesemolecule sites could be sensitive towards nucleophilic attacks.
All other complex molecules are characterized by the lowest MEP
values of around 45 kcal mol1, while in the highest MEP values
there are some diﬀerences. The ligand, L, is characterized by the
lowest charge separation, with the lowest magnitudes of negative
and positive MEP values. This low charge separation in the case
of the L molecule is also confirmed by the lowest dipole
moment (DP) of all the investigated structures in this work.
Fig. 1 MEP surfaces of L and its complexes.
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Although MEP surfaces are very useful for the determination
of molecule sites with significant reactive properties, when it
comes to the sensitivity towards electrophilic attacks, ALIE
surfaces are often a better choice since they indicate the
molecule sites where electrons are most easily removed from the
molecule. Murray et al.38–40 have defined ALIE as a sum of orbital
energies weighted by the orbital densities and used it initially to
understand the chemical reactivity of aromatic systems. The
equation for the calculation of ALIE I(r) is defined as:
IðrÞ ¼
X
i
ri ~rð Þ eij j
r ~rð Þ (2)
In eqn (2), ri(
-
r) denotes the electronic density of the i-th
molecular orbital at the point -r, while ei is the orbital energy.
ri(
-
r) is the total electronic density function. Representative ALIE
surfaces of all investigated structures in this work are presented
in Fig. 2. The range of the rainbow bar has been chosen
according to the lowest and the highest ALIE values in case of
the molecules investigated in this work.
Results of ALIE surfaces provided in Fig. 2 indicate that the
lowest ALIE value has been calculated in the case of the 3-L
complex. In this complex, the lowest ALIE values ofB150 kcalmol1
are located in the near vicinity of the bromine atom. Although
structurally 1-L and 3-L diﬀer in only one atom (3-L has a bromine
atom instead of one chlorine atom), they diﬀer significantly when it
comes to the lowest ALIE values and therefore their sensitivity
towards electrophilic attacks. Namely, the lowest ALIE value of 1-L
has been calculated to beB165 kcal mol1 and is located in the
near vicinity of chlorine atoms. Although the 4-L complex is not
recognized by the ALIE values as the most sensitive complex
towards electrophilic attacks, the color distribution confirms
the results obtained by the MEP values that the nitrogen atom
and the sulfur atom of the thiocyanate group are the most
sensitive atoms of 4-L towards electrophilic attacks. In general,
the topology of the lowest/highest MEP and ALIE values agrees
well for the structures investigated in this work.
Drug-likeness parameters
In recent decades, many useful computational descriptors and
correlation methods41 have been developed in order to screen
potential pharmaceutical candidates for practical applications
in drug formulations. In this work, we have calculated several
parameters that are most frequently used for the prediction of
drug-likeness of new compounds. Drug-likeness parameters,
usually addressed by the Lipinski’s rule of five,42,43 have been
summarized in Table 1.
According to standard criteria, it is desired that a potential
drug candidate has less than 5 and 10 HBD and HBA, respec-
tively. Concerning the molar refractivity, the desired range for
prospective drug candidates is between 40 and 130 m3 mol1
according to ref. 42. The number of atoms should be between
20 and 70, while the number of rotatable bonds should be less
than 10. These conditions are fulfilled by all molecules inves-
tigated in this work. PSA should not take values higher than
140 Å2 and the results provided in Table 1 indicate that the 4-L
molecule has just a slightly higher value for this descriptor.
However, one of the most important drug-likeness descrip-
tors is related to the lipophilic character of the drug candidate.
This property is usually measured by octanol/water partition
coeﬃcients (log P). There are several computational models to
predict the lipophilicity descriptor and in this work, we have
used the frequently employed c log P parameter,44–49 which
turned out to be a great choice in comparison with the other
models for the calculation of the log P parameter. Besides
c log P, it is also very useful to estimate the aqueous solubility
of a compound (c log S) which influences its absorption and
distribution characteristics. Both the c log P and c log S values
have been calculated by the DataWarrior software50 and listed
in Table 2 along with the calculated dipole moments (DPs).
According to the data,51 the highest percentage of traded
drugs has c log P values in the range between 2 and 4. However,
a significant number of commercially available drugs used in
clinical practice have c log P values in the range between 1 and
0. The data provided in Table 2 indicate that all the complex
Fig. 2 ALIE surfaces of L and its complexes.
Table 1 The calculated representative drug-likeness parameters
HBDa HBAb
Mass/
g mol1 PSAc/Å2
Refractivity/
m3 mol1
Number
of atoms
Rotatable
bonds
L 2 0 187.290 88.1300 53.0828 26 4
1-L 0 0 311.662 58.9100 42.7780 27 0
2-L 2 0 277.217 56.9700 45.2883 27 0
3-L 0 0 311.662 59.9100 42.7780 27 0
4-L 1 1 357.928 151.160 54.1696 31 0
a Hydrogen bond donors. b Hydrogen bond acceptors. c Polar surface
area.
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molecules investigated in this work have c log P values in the
range between 0.6 and 0, which makes them promising
candidates for pharmaceutical purposes. Additionally, according
to the same source,52 the highest number of traded drugs has
c logS values in the range between4 and2. In this regard, it is
particularly interesting to notice that complexes 4-L and 1-L
have c log S values between 3.2 and 3.7, which completely
corresponds to the desired range. At the same time, the c log S
value of the 2-L complex is equal to 1.8, which is very close to
the desired value of 2. Of all the complex molecules, the
complex 3-L has the worst value of c log S parameter (0.011).
However, its c log S value, due to the mentioned facts, is still
interesting.
Complexes as carriers of cisplatin
Cisplatin (cisp) belongs to a group of compounds widely and
frequently used for the treatment of various cancerous diseases.
In this work, we have considered the possibility that our newly
synthesized complexes could serve as carriers of cisp, from both
experimental and computational aspects.
From the computational aspects, we have considered the
interactions between the complexes and cisp by investigation of
noncovalent interactions and binding energies. Ground state
geometries of the systems consisting of the complex and cisp
together with visualized noncovalent interactions between the
complexes and cisp are presented in Fig. 3.
According to the results shown in Fig. 3, binding between
the complexes and cisp is based on electrostatic interactions,
since no new bonds have been formed. This is of particular
interest since the release of cisp could be achieved under easier
conditions than, for example, if binding were based on chemical
interactions.
Next, we refer to the binding energies between the complexes
and cisp, which have been calculated at the LMP2 and DFT
levels of theory (Fig. 4).
Binding energies have been calculated at both the LMP2 and
DFT levels of theory. The LMP2 level of theory has been used
since it is ‘‘immune’’ to the basis superposition error and it
does not require the usage of counterpoise correction. On the
other side the LMP2 level of theory is not available in many
molecular modeling packages so we decided to calculate binding
energies at the DFT/B3LYP-D3 level of theory as well, which is a
level of theory that is readily available in all molecular modeling
packages capable of dealing with DFT calculations and which is
recommended in cases when noncovalent interactions take
place.53–55 Although the LMP2 and DFT levels of theory provide
expectedly different values of binding energies, the trends are
completely in agreement. According to the binding energies, the
strongest interaction occurs in the case of the system consisting
of the 4-L complex and cisp, with the corresponding binding energy
of 64 kcal mol1 at the LMP2 level of theory (61 kcal mol1 at
DFT level of theory). The 1-L and 3-L complexes have very similar
binding energies (around 43 kcal mol1), as calculated at the
LMP2 level of theory (around54 kcal mol1 at DFT level of theory).
The lowest binding energy has been calculated in the case of
complex 2-L and cisp, with the corresponding binding energy
of 14 kcal mol1 as calculated at the LMP2 level of theory
(18 kcal mol1 at the DFT level of theory).
The results shown in Table 2 indicate that the 4-L complex
has the most representative c log P and c log S values of all the
investigated complexes in this study. At the same time, this
complex has the highest binding interaction with the cisp
compound, indicating that it can not only permeate the barrier,
but also serve as a carrier of cisp and have an interesting synergistic
eﬀect. Although the 2-L complex has the lowest binding energy with
cisp, that binding energy is still high enough to be considered as a
Table 2 c logP, A logP, c log S and DP values for all investigated molecules
c log P A logP c log S DP
L 2.4842 0.59 1.195 5.37
1-L 0.5715 1.16 3.403 9.42
2-L 0.2394 1.16 1.829 8.78
3-L 0.5715 2.75 0.011 9.70
4-L 0.0592 3.55 3.197 15.58
Fig. 3 Interactions of cisp with the complexes.
Fig. 4 Binding energies between the complexes and cisp.
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possible carrier of cisp. On the other side, the much lower binding
energy with cisp would mean an easier release of cisp as well,
which could be an important factor for the eﬃcient practical
application of this complex.
Determination of combination index
To see how the experimental results can be related to the
calculated parameters, the combination indices (CIs) for the
ligands and the corresponding coordination compounds were
determined. Determination of the combination index is a useful,
resource saving method for in vitro testing of the combination of
two or more active compounds.56 In order to see how the Schiﬀ
base type ligands L, L1, and L2 and their complexes influence the
eﬀect of the standard cisplatin drug, dilutions of the compounds
were mixed with cisp and applied on multidrug-resistant mouse
T-lymphoma cells overexpressing the ABCB1 transporter.
Table 3 lists the combination indices of L and its copper(II)
complexes 1, 2, 3 and 4 along with the CIs of the L1 and L2
ligands and their Co(III), Ni(II), Cu(II) and Zn(II) complexes,
respectively.31,32 The referent CI values are given in Table 5.
The ligand L (Scheme 1) and its coordination compounds in
combination with cisp show all three eﬀects (Table 3). Strong
antagonism is characteristic for the ligand, L, and for complex
1 with two coordinated chlorides. 3 containing one coordinated
chloride and one bromide shows an additive eﬀect, while
complexes 2 and 4 with one coordinated chlorido and thiocyanato
ligand, respectively, showmoderate synergism. These observations
might be correlated with the role of the halido ligands and their
position in the complexes. Complexes 1, 2 and 3 have square-
pyramidal geometry while 4 has a square-planar arrangement
around the central atom. In 1, with the chlorido ligands in the
cis position, antagonism is detected. Compound 3 with the mixed
chlorido and bromido ligands shows an additive eﬀect. For 2 with
a coordinated chloride ion (and MeOH in the solid state) and for
the quasi square-pyramidal complex 4 with one coordinated
thiocyanato ligand in the basal plane and the second one in
the apical position, a moderate synergism is characteristic. As
the molar conductivity data in N,N-dimethylformamide (DMF)
solution refer to an electrolyte of 1 : 1 type for 2, while to 4 as a
non-electrolyte,1 in solution both compounds have a similar
geometry.
The diﬀerence between the ligands L1 and L2 is that L1 is a
bis(3-chloropyridazine-6-hydrazone) derivative of 2,6-diacetyl-
pyridine while L2 is the bis(phthalazine-1-hydrazone)-2,6-
diacetylpyridine (Scheme 2). Ligand L1 shows moderate synergism
with cisp. Coordination compounds of Co(II) and 1-L1, and Ni(II)
and 2-L1, show antagonism with cisp. The Cu(II) complex, 3-L1,
displays moderate synergism with cisp, while the zinc(II)
compound, 4-L1, exhibits strong synergism with cisp.
On the contrary, while screening reveals synergism between
L2 (Scheme 2) and cisp, the Co(III) complex (1-L2) acts as an
antagonist to cisp, 2-L2 with a Ni(II) center acts as a synergist,
3-L2 with Cu(II) shows an additive eﬀect and the Zn(II) complex,
4-L2, displays strong synergism.
As all four complexes with L1 are ion-neutral complexes,
with no additional ligands, their diﬀerent behavior with cisp is
due exclusively to the diﬀerent central ions and/or geometry.31
On the other hand, complexes 1–3 with L2 contain chloride
ions, too, but have different geometries. In 1-L2 the central
Co(III) has an octahedral surrounding with two chloride ions in
the trans position. The Ni(II) complex, 2-L2, adopts a square-
planar structure and the chloride ion is not coordinated. In 3-L2
a square-pyramidal arrangement around Cu(II) is established
with the chloride ion in the apical position. In addition, complexes
1-L2 and 3-L2 are non-electrolytes in DMF while 2-L2 is a 1 : 1
electrolyte,32 so their different action with cisp is expected.
The activity of cisplatin depends on the hydrolysis of its
chloride ligands. This process in vivo is hindered in the blood-
stream, with a stable chloride concentration of 100 mM. Inside
the cell, the Cl concentration is significantly lower (4–20 mM)
and therefore assists the hydrolysis.57 Compounds containing
chloride ions may alter the chloride concentration in the cellular
media, and therefore could have an impact on the anticancer
effects of cisplatin. Among the tested compounds ligands L and
Table 3 Combination indices of L1, L2, and L3 and their complexes with
cisplatin
Compound
Cisplatin
CI (ED50) Type of interaction
L 3.81 Strong antagonism
1-L 2.05 Antagonism
2-L 0.80 Moderate synergism
3-L 1.08 Additive eﬀect
4-L 0.75 Moderate synergism
L1 0.78 Moderate synergism
1-L1 1.79 Antagonism
2-L1 1.51 Antagonism
3-L1 0.84 Moderate synergism
4-L1 0.31 Strong synergism
L2 0.37 Synergism
1-L2 2.52 Antagonism
2-L2 0.47 Synergism
3-L2 1.02 Additive eﬀect
4-L2 0.26 Strong synergism
Scheme 1 Structure of the ligand L.
Scheme 2 Structures of the ligands L1 and L2.
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L2 crystallize with HCl; the counter-ion in complex 2-L2 is
chloride, while in the coordination complexes 1L–3L and 1-L2
and 3-L2 the chloride ion is coordinated, so in their combination
with cisp, the chloride ion may take part in the interactions.
However, the M–Cl bond lengths vary in the range of 2.20–2.26 Å1,32
and thus it is very difficult to say anything about their actual
involvement in the reactions.58
Apart from the role of the chloride ions, the targets of metal
complexes in vivo are diverse. The primary targets are nucleic
acids, redox processes, mitochondria and proteins.59 The protein
binding of cisp is cc. 95% in vivo. Any compound which binds
to plasma proteins (e.g. albumin) more competitively will
proportionally increase the amount of free (pharmacologically
active) drug in the system.60
Cisplatin exerts its activity by forming bifunctional intra-
and interstrand crosslinks (platinating) through covalent
bonds with DNA on its nucleophilic sites (the N7 atoms of
adenine and guanine-purine nucleosides are the most nucleo-
philic), although it has been observed that only around 1% of the
agent inside the cell is found in the nuclei of cells, and around
5–10% of cisp reacts with DNA, while much of the agent is
involved in reactions with a diverse range of other biomolecules,
such as protein-platinum complexes.59 Some hypotheses suggest
that using combinational agents with cisplatin can affect the
stability of the said DNA-crosslinks, sensitize or desensitize several
biomolecules to the effect of the drug, and influence the amount
of cisplatin penetrating the nucleus, thus modifying the extent of
the potential anticancer effects by a considerable margin.61
Crosslinks in DNA lead to the termination of transcriptional
processes and eventually cell death. However, according to recent
literature data, more than one mechanism could have a role in the
anticancer eﬀects of platinum-based anticancer agents. The
diﬀerent reaction paths could potentially serve as an explanation
for the interactions with Schiﬀ base type compounds and their
coordination complexes. A novel cell death mechanism, ferro-
ptosis, has been implicated in the cell death caused by the
platinum complexes. Ferroptosis is a type of regulated cell death
(RCD) which is most predominantly induced by iron-dependent
ROS production and subsequent lipid-peroxidation.62 In theory,
cisplatin adversely aﬀects iron-metabolism inside the cells,
activating the pathways implicated. Since the metal complexes
can probably modulate the homeostasis of metal ions inside the
cells, their activity should influence the activity of cisp.
Evidence suggests that cisplatin aﬀects the proteins of the
signal transducer and activation of transcription (STAT) path-
way, especially STAT3, which results in direct inhibition of the
STAT signaling pathway.63 The platinum-based drugs inhibit de
novo STAT protein phosphorylation, and if the Schiﬀ base type
compounds also exert STAT protein modulating activities, then
this field could also present an area of potential pharmacological
interactions. The upregulation of phospho-p53 was also observed
in cisplatin-treated cells, which is another viable route to
drug–drug interactions if the tested compounds possess such
activity.64,65
Cisplatin can enter the target cells by passive transport as well
as by relying on the CTR1 copper transporter. Compounds with
the ability to regulate the expression and/or activity of the
transporters will alter the pharmacological potency of the
chemotherapeutic drug.66 As complex 4-L has the highest
binding interaction with cisp, it definitely could serve as its
carrier. Although the binding energy of 2-L is the lowest, it still
may be a drug carrier. On the other hand, the lower binding
energy means an easier release of cisp. Indeed, only these two
compounds in the L series show a synergistic eﬀect with cisp.
Being a metal complex itself, cisplatin can interact with a
multitude of pharmacologically active molecules in many ways.
Apart from steric interactions between the molecules (described
in the article elsewhere), conditions may allow for the association
of novel drug complexes or drug macrostructures in a biological
environment.67 These macrostructures could have physico-
chemical properties not resembling the original parent molecules
which, in turn, is observed in their diﬀerent (enhanced or
suppressed) biological activities.
The calculated parameters and c log P values for the L series
well follow the trend of the determined IC values. Also, the
correlation of the dipole moments shows a relatively good
agreement with the IC data while the other calculated para-
meters cannot be unambiguously related to the measured
eﬀect. Copper(II) compounds from all three series show an
additive eﬀect or synergism with cisp except that with L2, while
compounds with Co(III), Ni(II) and Zn(II) exhibit diﬀerent types
of interactions. While both the L1 and L2 ligands show a
synergistic eﬀect, strong antagonism was found for L. A highly
probable explanation for this behavior is that the NH2 groups of
the guanidine substituent of Lmay replace the chloride in cisp,
in this way hindering its bioavailability. In an in vitro environment,
the possible antagonism of L can also be explained by its coordina-
tion to the platinum, as cisp has good leaving NH3 ligands, forming
thus a stable chelate complex which shows no activity.
Thermal data
The practical applicability of new compounds and materials, gen-
erally, depends to a large extent on their thermal properties.21,68–72
In addition, using isothermal titration calorimetry, the interactions
between biomolecules can be measured.73 Sometimes, the thermal
stability and biological activity of bioactive molecules may be
correlated and partly explained.74 Therefore, the thermal
decomposition of L and its complexes 1–4L was determined.
The thermoanalytical data and a detailed description of the
mechanism of the decomposition are given in the ESI.† Here
only the most important data are discussed.
The thermogravimetric curves of all the complexes are in
agreement with the structural data. In compound 2-L the
coordinated MeOH evaporates at a rather high temperature
(118 1C onset), though its amount (Dmexp = 3.2%, Dmcalcd =
8.65%) is significantly less than the stoichiometric one, probably
as a consequence of its evaporation accompanied by structural
rearrangement of the lattice.75,76 In compound 1-L traces of water
were found. Except for complex 4-L (DTG onset 159 1C), the
desolvated ligand and its complexes are stable to above 200 1C,
and therefore their thermal stability would have an insignificant
eﬀect on the eventual drug manufacturing.
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While the thermal curves of the coordination compounds are in
agreement with the structure and the composition determined by
the X-ray structure analysis, the ligand, L, on the basis of the EGD
data contains 2 molecules of crystal water, L2HCl2H2O (Dmexp =
12.6%, Dmcalcd = 12.59%) which evaporate at 120 1C. However, after
the water evaporation, the ligand is stable up to 210 1C DTG onset.
Despite that the thermal stability of the compound and the
corresponding calculated molecular descriptors are seemingly
not related, Table 4 shows a relatively good Pearson correlation
(PCC) coeﬃcients between several parameters, calculated in
this work and the DTG onset temperatures. Among others, it
can be seen that the thermal stability of the compounds (DTG
onset data) with enough statistical significance (p) nicely correlates
with the dipole moments, A logP and PSA. The highest correlation
has been obtained in the case of DTG onset versus PSA parameters,
with an inverse proportional character. Somewhat lower, but still
significant is the correlation of the DTG onsets in the case of
dipole moments and A logP parameters. As A logP and PSA are
parameters related to pharmacokinetics, while dipole moments
are related to charge distribution, it can be considered that the
correlation of the DTG onsets with the dipole moments might be
of particular importance. According to the data provided in
Table 4, the DTG onset temperatures and the dipole moments
are inversely proportional.
Experimental
Synthesis
The details of the synthesis and the characterization of the
ligand L2HCl and its complexes [CuLCl2] (1), [CuL(Cl)MeOH]NO3
(2), CuL(Cl)Br (3) and [CuL(NCS)(SCN)] (4) are given in ref. 1. The
synthesis and characterization of the ligand L1 and its coordination
complexes with 3d metals have been described previously, together
with their antitumor and multidrug resistance reversing activities.31
The synthesis and structures of the ligand L2 and its complexes are
also published.32 L1 and L2 here denote the bis(3-chloropyridazine-
6-hydrazone)-2,6-diacetylpyridine and bis(phthalazine-1-hydrazone)-
2,6-diacetylpyridine ligands and their complexes with Co(III), Ni(II),
Cu(II) and Zn(II) are numbered as 1, 2, 3 and 4, respectively. The
coordination structures of the solid compounds with L1 and L2 are
as follows: [Co2(m-L1–2H)2(m-O2)]4H2O, [Ni(L1–2H)], [Cu(L1–2H)]
H2O, [Zn(L1–2H)]H2O and complexes [Co(L2–H)Cl2]MeOH,
[Ni(L2–H)]ClMeOH, [Cu(L2–H)Cl] and [Zn(L2–2H)]H2O. To
get the amount of compound needed for assays, the compounds
were re-synthesized.
Computational details
Dispersion-corrected density functional theory (DFT-D3)77,78 and
local second-order Moller-Plesset perturbation theory (LMP2)79,80
calculations have been done by the Jaguar 9.6 program,81 as
implemented in Schro¨dinger Materials Science Suite 2017-2.82
The DFT-D3 calculations were done with a dispersion corrected
B3LYP83,84 hybrid exchange–correlation functional, namely the
B3LYP-D3 functional. LACVP basis sets have been employed as
well. The LMP2 calculations were done considering all atom
pairs. Geometrical optimizations were performed without any
constraints, with increased grid size and integral accuracy. In all
cases, geometrical optimizations and vibrational analysis were
conducted in order to assure that true ground states, character-
ized by the absence of imaginary frequencies, were identified.
Noncovalent interactions were identified according to the studies
in ref. 85 and 86. After obtaining ground state geometries, the
MEP and ALIE values were obtained after single point energy
calculations. The MEP and ALIE values were mapped to the
electron density surface in order to identify reactive molecule
areas. Interaction energies were obtained at the LMP2 level of
theory, for which it is not needed to include counterpoise
correction for basis superposition error.
Biological measurements
The compounds used as reagents were: cisplatin (TEVA Phar-
maceutical Company, Petah Tikva, Israel), 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, St Louis,
MO, USA), sodium dodecyl sulfate (SDS; Sigma) and dimethyl
sulfoxide (DMSO; Sigma). The ligands and the complexes were
dissolved in DMSO to obtain stock solutions. The concentration
of DMSO was below 1% in all the experiments. All solutions were
prepared on the day of the assay.
Cell lines
L5178Y mouse T-cell lymphoma cells (PAR) (ECACC Cat. No.
87111908, obtained from FDA, Silver Spring, MD, USA) were
transfected with pHa MDR1/A retrovirus, as previously described
by Cornwell et al.87 The ABCB1-expressing cell line L5178Y (MDR)
was selected by culturing the infected cells with colchicine. The
L5178Y human ABCB1-transfected subline was cultured in McCoy’s
5A medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with
10% heat-inactivated horse serum (Sigma-Aldrich, St Louis, MO,
USA), 2 mM L-glutamine (Sigma-Aldrich, St Louis, MO, USA) and a
penicillin–streptomycin (Sigma-Aldrich, St Louis, MO, USA)mixture
in concentrations of 100 U L1 and 10 mg L1, respectively. The
dose of penicillin is defined in international units (IU or U); 1 mg of
pure penicillin G potassium equals 1595 U.
Table 4 Pearson correlation coeﬃcient of selected parameters calcu-
lated in this work
Biology DTG DP A logP PSA Refractivity
Biology PCC 1.000 0.370 0.736 0.542 0.039 0.407
p 0.539 0.157 0.345 0.950 0.496
DTG PCC 0.370 1.000 0.889 0.885 0.925 0.603
p 0.539 0.044 0.046 0.024 0.282
DP PCC 0.736 0.889 1.000 0.848 0.679 0.215
p 0.157 0.044 0.070 0.208 0.728
A log P PCC 0.542 0.885 0.848 1.000 0.690 0.324
p 0.345 0.046 0.070 0.198 0.595
PSA PCC 0.039 0.925 0.679 0.690 1.000 0.854
p 0.950 0.024 0.208 0.198 0.065
Refractivity PCC 0.407 0.603 0.215 0.324 0.854 1.000
p 0.496 0.282 0.728 0.595 0.065
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Checkerboard combination assay
A checkerboard microplate method was applied to study the
eﬀect of drug interactions between the Schiﬀ bases and their
coordination compounds and the reference chemotherapeutic drug
cisplatin, thus to determine the CI for the compounds.56,58,88
The assay was carried out using multidrug-resistant mouse
T-lymphoma cells overexpressing the ABCB1 transporter. The
starting concentration of cisplatin (10 mgmL1; from a 0.5mgmL1
stock solution) was determined during preliminary experiments
on multidrug-resistant mouse T-lymphoma cells and starting
concentrations of the tested compounds were determined
according to previous experimental results. The dilutions of
cisplatin were made in a horizontal direction in 100 mL, and the
dilutions of the tested compounds were made vertically in the
microtiter plate in 50 mL volume. The cells were re-suspended in
the culture medium and distributed into each well in 50 mL
containing 6 103 cells each. The plates were incubated for 72 h
at 37 1C in 5% CO2 atmosphere. The cell growth rate was
determined after MTT staining. At the end of the incubation
period, 20 mL of MTT (thiazolyl blue tetrazolium bromide,
Sigma) solution (from a stock solution of 5 mg mL1) were
added to each well. After incubation at 37 1C for 4 h, 100 mL of
sodium dodecyl sulfate (SDS) (Sigma) solution (10% in 0.01 M
HCI) was added to each well and the plates were further
incubated at 37 1C overnight. Optical density (OD) was mea-
sured at 540/630 nm with a Multiscan EX ELISA reader (Thermo
Labsystems, Cheshire, WA, USA) as described elsewhere.89
Combination index (CI) values at 50% of the growth inhibition
dose (ED50), were determined using CompuSyn software (Combo-
Syn, Inc., Paramus, NJ. 07652 USA) to plot four to five data points for
each ratio. The CI values were calculated by means of the median-
eﬀect equation, according to the Chou-Talalay method 3–5, where
CIo 1, CI = 1, and CI4 1 represent synergism, additive effect
(or no interaction), and antagonism, respectively. The referent
CI values are given in Table 5.88
Thermal analysis
Thermal data and the detection of evolved gases (EGD) were
measured using a TA Instruments SDT Q600 thermal analyzer
coupled to a Hiden Analytical HPR-20/QIC mass spectrometer from
room temperature to 550 1C at 10 1Cmin1 heating rate in nitrogen
carrier gas (flow rate: 50 cm3 min1) withB4 mg sample mass.
The sample holder and the reference were an alumina crucible
and an empty alumina crucible. Selected ions between m/z =
1–120 were monitored in Multiple Ion Detection Mode (MID).
Conclusions
In order to get a better insight into the mechanism of action of
potentially bioactive Schiﬀ-base type ligands and their coordination
complexes with 3d metal ions in combination with the chemo-
therapeutic drug cisplatin, the combination indices (CIs) were
determined by the checkerboard microplate method using L5178Y
mouse T-cell lymphoma cells transfected with pHa MDR1/A retro-
virus (MDR) with respect to the chemotherapeutic drug cisplatin
reference. The tested compounds were 2-acetylpyridine-amino-
guanidine and its copper(II) complexes containing additional
monoanionic ligands, as well as bis(3-chloropyridazine-6-hydrazone)-
2,6-diacetylpyridine and bis(phthalazine-1-hydrazone)-2,6-diacetyl-
pyridine and their Co(III), Ni(II), Cu(II) and Zn(II) complexes.
DFT and LMP2 calculations were carried out for the 2-acetyl-
pyridine-aminoguanidine ligand, L, and its copper(II) complexes
with diﬀerent monoanionic ligands. TheMEP and ALIE surfaces
and drug-likeness parameters (PSA, the number of atoms and
rotatable bonds as well as the c logP, c logS, and DP) were
calculated for the compounds. In order to estimate the possibility
of the compounds as drug carriers, the noncovalent interactions
and binding energies were also calculated. On the basis of these
calculations, practically all the compounds satisfy the criteria as
potential drug candidates. The c logS values for 4-L and 1-L are in
the optimal range, and complex 1-L shows an optimum value for
c logP, too. The highest binding energy between the compound
and cisplatin was found for the 4-L complex, while the lowest one
belonged to the compound 2-L and cisp which is still high enough
for 2-L to be a drug carrier, but having the advantage of easier drug
release.
Compounds 4-L and 2-L show a synergistic eﬀect with cisp,
indicating their possible role as drug carriers. The c log P values
well follow the trend of the determined IC values. The dipole
moments are also in relatively good agreement with the IC data,
while the other calculated parameters cannot be unambiguously
related to the IC data.
Another interesting phenomenon was observed concerning
the thermal stability of the compounds. Namely, the DTG onset
data with enough statistical significance correlate with A log P
and PSA. The DTG onsets and the dipole moments are inversely
proportional and the correlation between them is still significant.
The relationship between the thermal stability and the biological
activity of a series of compounds with a similar composition and
structure to our knowledge has not yet been explored in the
literature as it is associated with seemingly not related properties.
However, the thermal stability is related to the binding energies of
the molecules; therefore, it might be of interest in the future
investigations of compound series with potential biological activity.
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Table 5 Summary of interaction types related to calculated combination
index (CI) values
CI Interaction
0–0.1 Very strong synergism
0.1–0.3 Strong synergism
0.3–0.7 Synergism
0.7–0.85 Moderate synergism
0.85–0.9 Slight synergism
0.9–1.1 Additive eﬀect
1.1–1.2 Slight antagonism
1.2–1.45 Moderate antagonism
1.45–3.3 Antagonism
3.3–10 Strong antagonism
410 Very strong antagonism
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